Florida A&m University

Madhavi Gangapuram

Kinfe Ken Redda

Elizabeth Anne Mazzio

Elizabeth Henderson

Karam F A Soliman

Tiffany Wilson Ardley

Novel compositions and methods of using the compositions to treat triple negative breast cancer are presented. 4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide has been shown to downregulate the expression of several genes associated with TNBC such as amphiregulin (AREG), epiregulin (EREG), inhibitor of DNA binding 1 (ID1), inhibitor of DNA binding 3 (ID3), killer cell lectin like receptor C3 (KLRC3), cyclooxygenase-2 (COX2), and intercellular adhesion molecule 1 (ICAM-1). In addition, the compound has been shown to downregulate the oncostatin M(OSM) signaling pathway.

Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancer

Disclosed herein is the use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetra-hydropyridine as a treatment for cancer.

Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer

The compounds herein disclosed are N-substituted tetrahydroisoquinoline benzamide and benzene sulfonamide compounds that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-substituted tetrahydroisoquinoline compounds have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have ICvalues against the breast cancer cells that are 6- to 10-fold less than the ICof Tamoxifen.

N-substituted tetrahydroisoquinoline benzamides/benzene sulfonamides as anti-cancer agents

The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have ICvalues against the breast cancer cells that are 6-10-fold less than the ICof tamoxifen.

N-aminotetrahydroisoquinolines as anti-cancer agents

The compounds herein disclosed are N-aminopyrrolylmethyltetrahydropyridine analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-aminopyrrolylmethyltetrahydropyridines have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have ICvalues against the breast cancer cells that are 6-10-fold less than the ICof tamoxifen.

Growing community of inventors

Tallahassee, FL, United States of America

Madhavi Gangapuram